References
- Guindon GE, Boisclair D. Past, current, and future trends in tobacco use, 2nd ed. Washington, (DC): The World Bank, 2003. Available at: www.worldbank.org/tobacco/publications.asp [Last accessed March 1, 2007]
- Rodgers A. Quantifying selected major risks to health. The World Health Report 2002: reducing risks, promoting healthy lifeCampanini B, Haden A. Geneva, (Switzerland): World Health Organization, 2002;47–98
- Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442
- Peto R, Lopez A. Future worldwide health effects of current smoking patterns. Critical issues in global healthKoop CE, Pearson CE, Schwartz MR. San Francisco (CA): Jossey-Bass, 2001;155
- Coe JW, Brooks PR, Vetelino MG, . Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005; 48:3474–7
- Nides M, Oncken C, Gonzales D, . Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006; 166:1561–8
- Oncken C, Gonzales D, Nides M, . Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med 2006; 166:1571–7
- Anon. Clearing the air: how to quit smoking and quit for keeps. Publication 95–1647Bethesda, (MD): National Institutes of Health, National Cancer Institute, 1995
- Fiore MC. US public health service clinical practice guideline: treating tobacco use and dependence. Respir Care 2000; 45:1200–62
- Fiore MC, Bailey WC, Cohen SJ, . Treating tobacco use and dependence. Clinical practice guidelineRockville, (MD): US Department of Health and Human Services, Public Health Service, 2000
- Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986; 43:289–94
- Cappelleri JC, Bushmakin AG, Baker CL, . Revealing the multidimensional framework of the Minnesota Nicotine Withdrawal Scale. Curr Med Res Opin 2005; 21:749–60
- Rose JE, Behm FM, Westman EC. Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol 1998; 6:331–43
- Nakamura M, Oshima A, Fujimoto Y, . Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled dose–response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007; 29:1040–56
- Tsai S-T, Cho H-J, Cheng H-S, . A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007; 29:1027–39
- Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2004. CD000031
- Silagy C, Lancaster T, Stead L, . Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004. CD000146
- Gonzales D, Rennard SI, Nides M, . Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. J Am Med Assoc 2006; 296:47–55
- Jorenby DE, Hays JT, Rigotti NA, . Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs. placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. J Am Med Assoc 2006; 296:56–63